Roche/Corange divesting Retavase to Centocor; biotech firm to co-promote ReoPro with Lilly.
Executive Summary
CENTOCOR TO PROMOTE RETAVASE, REOPRO WITH 200-PERSON SALES FORCE following the proposed acquisition of Retavase (reteplase, r-PA) from Roche/Boehringer Mannheim. Under the agreement announced Feb. 12, Centocor will pay $335 mil. in cash to acquire U.S. and Canadian rights to Boehringer Mannheim's Retavase and will offer "to employ, upon closing of the transaction, many U.S.-based sales and marketing personnel who currently commercialize the product," the Malvern, Pa.-based firm said.
You may also be interested in...
Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011